Limits...
Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.

Minichsdorfer C, Wasinger C, Sieczkowski E, Atil B, Hohenegger M - Melanoma Res. (2015)

Bottom Line: The effects of IL-6 were measured by western blots for STAT3 and Bcl-2 family proteins.This proapoptotic effect of IL-6 might be explained by a downregulation of Bcl-XL, observed only in WM35 cells.These results confirm that simvastatin facilitates apoptosis in combination with IL-6.

View Article: PubMed Central - PubMed

Affiliation: aDepartment of Oncology, Medicine I bCenter for Physiology and Pharmacology, Comprehensive Cancer Center, Institute of Pharmacology cDepartment of Neurology, Medical University of Vienna, Vienna, Austria.

No MeSH data available.


Related in: MedlinePlus

Cell cycle analysis of interleukin (IL)-6-treated human melanoma cells. Melanoma cells (a) 518A2, (b) A375, and (c) WM35 were incubated with IL-6 (20 ng/ml) under serum-free conditions for 48 h and compared with controls (CTL). For cell cycle analyses, cells were stained with propidium iodide and analyzed by FACS. Normalized data represent the mean±SD (n=6). Statistical significance versus control: *P<0.05; **P<0.01; ***P<0.001.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4492793&req=5

Figure 2: Cell cycle analysis of interleukin (IL)-6-treated human melanoma cells. Melanoma cells (a) 518A2, (b) A375, and (c) WM35 were incubated with IL-6 (20 ng/ml) under serum-free conditions for 48 h and compared with controls (CTL). For cell cycle analyses, cells were stained with propidium iodide and analyzed by FACS. Normalized data represent the mean±SD (n=6). Statistical significance versus control: *P<0.05; **P<0.01; ***P<0.001.

Mentions: These results were further corroborated by analyses of the cell cycle, which showed a significant stimulation of the G2 phase in A375 and 518A2 cells by IL-6 (Fig. 2). Conversely, WM35 cells accumulate in the G0/G1 phase, reflecting a reduction of cell cycle progression in the presence of IL-6 (Fig. 2c).


Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.

Minichsdorfer C, Wasinger C, Sieczkowski E, Atil B, Hohenegger M - Melanoma Res. (2015)

Cell cycle analysis of interleukin (IL)-6-treated human melanoma cells. Melanoma cells (a) 518A2, (b) A375, and (c) WM35 were incubated with IL-6 (20 ng/ml) under serum-free conditions for 48 h and compared with controls (CTL). For cell cycle analyses, cells were stained with propidium iodide and analyzed by FACS. Normalized data represent the mean±SD (n=6). Statistical significance versus control: *P<0.05; **P<0.01; ***P<0.001.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4492793&req=5

Figure 2: Cell cycle analysis of interleukin (IL)-6-treated human melanoma cells. Melanoma cells (a) 518A2, (b) A375, and (c) WM35 were incubated with IL-6 (20 ng/ml) under serum-free conditions for 48 h and compared with controls (CTL). For cell cycle analyses, cells were stained with propidium iodide and analyzed by FACS. Normalized data represent the mean±SD (n=6). Statistical significance versus control: *P<0.05; **P<0.01; ***P<0.001.
Mentions: These results were further corroborated by analyses of the cell cycle, which showed a significant stimulation of the G2 phase in A375 and 518A2 cells by IL-6 (Fig. 2). Conversely, WM35 cells accumulate in the G0/G1 phase, reflecting a reduction of cell cycle progression in the presence of IL-6 (Fig. 2c).

Bottom Line: The effects of IL-6 were measured by western blots for STAT3 and Bcl-2 family proteins.This proapoptotic effect of IL-6 might be explained by a downregulation of Bcl-XL, observed only in WM35 cells.These results confirm that simvastatin facilitates apoptosis in combination with IL-6.

View Article: PubMed Central - PubMed

Affiliation: aDepartment of Oncology, Medicine I bCenter for Physiology and Pharmacology, Comprehensive Cancer Center, Institute of Pharmacology cDepartment of Neurology, Medical University of Vienna, Vienna, Austria.

No MeSH data available.


Related in: MedlinePlus